Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of GSK5733584 in advanced solid tumors
jRCT2031240279Phase 1Recruiting
- Sponsor
- GSK
- Start
- Sep 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of mocertatug rezetecan in Nonhematologic neoplasms, endometrial cancer (EC) and ovarian cancer (3 cohorts), sponsored by GSK. Primary endpoints: Number of participants with dose-limiting toxicity and Objective response rate. Started Sep 2024; status: recruiting.
02
Drugs
mocertatug rezetecan
03
Conditions
Nonhematologic neoplasmsendometrial cancer (EC)ovarian cancer
Beyond the preview
Go deeper on jRCT2031240279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240279.